In a report released yesterday, Arsene Guekam from Kepler Capital maintained a Sell rating on Alcon (ALC), with a price target of CHF50.00. The company’s shares closed last Monday at $48.28.
According to TipRanks.com, Guekam is a 1-star analyst with an average return of -6.7% and a 21.4% success rate. Guekam covers the Healthcare sector, focusing on stocks such as Innate Pharma SA, Crossject SA, and Pharnext SA.
Currently, the analyst consensus on Alcon is a Hold with an average price target of $60.60.
See today’s analyst top recommended stocks >>
The company has a one-year high of $65.37 and a one-year low of $39.37. Currently, Alcon has an average volume of 1.26M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Fribourg, Switzerland.
